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Microarray analysis of retinal gene expression in Egr-1 knockout
mice
Ruth Schippert, Frank Schaeffel, Marita Pauline Feldkaemper
Institute for Ophthalmic Research, Section of Neurobiology of the Eye, University Eye Hospital Tuebingen, Tuebingen, Germany
Purpose: We found earlier that 42 day-old Egr-1 knockout mice had longer eyes and a more myopic refractive error
compared to their wild-types. To identify genes that could be responsible for the temporarily enhanced axial eye growth,
a microarray analysis was performed in knockout and wild-type mice at the postnatal ages of 30 and 42 days.
Methods: The retinas of homozygous and wild-type Egr-1 knockout mice (Taconic, Ry, Denmark) were prepared for
RNA isolation (RNeasy Mini Kit, Qiagen) at the age of 30 or 42 days, respectively (n=12 each). Three retinas were pooled
and labeled cRNA was made. The samples were hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays.
Hybridization signals were calculated using GC-RMA normalization. Genes were identified as differentially expressed if
they showed a fold-change (FC) of at least 1.5 and a p-value <0.05. A false-discovery rate of 5% was applied. Ten genes
with potential biologic relevance were examined further with semiquantitative real-time RT–PCR.
Results: Comparing mRNA expression levels between wild-type and homozygous Egr-1 knockout mice, we found 73
differentially expressed genes at the age of 30 days and 135 genes at the age of 42 days. Testing for differences in gene
expression between the two ages (30 versus 42 days), 54 genes were differently expressed in wild-type mice and 215
genes in homozygous animals. Based on three networks proposed by Ingenuity pathway analysis software, nine differently
expressed genes in the homozygous Egr-1 knockout mice were chosen for further validation by real-time RT–PCR, three
genes in each network. In addition, the gene that was most prominently regulated in the knockout mice, compared to wild-
type, at both 30 days and 42 days of age (protocadherin beta-9 [Pcdhb9]), was tested with real-time RT–PCR. Changes
in four of the ten genes could be confirmed by real-time RT–PCR: nuclear prelamin A recognition factor (Narf),
oxoglutarate dehydrogenase (Ogdh), selenium binding protein 1 (Selenbp1), and Pcdhb9. Except for Pcdhb9, the genes
whose mRNA expression levels were validated were listed in one of the networks proposed by Ingenuity pathway analysis
software. In addition to these genes, the software proposed several key-regulators which did not change in our study:
retinoic acid, vascular endothelial growth factor A (VEGF-A), FBJ murine osteosarcoma viral oncogene homolog
(cFos), and others.
Conclusions: Identification of genes that are differentially regulated during the development period between postnatal
day 30 (when both homozygous and wild-type mice still have the same axial length) and day 42 (where the difference in
eye length is apparent) could improve the understanding of mechanisms for the control of axial eye growth and may lead
to potential targets for pharmacological intervention. With the aid of pathway-analysis software, a coarse picture of
possible biochemical pathways could be generated. Although the mRNA expression levels of proteins proposed by the
software, like VEGF, FOS, retinoic acid (RA) receptors, or cellular RA binding protein, did not show any changes in our
experiment, these molecules have previously been implicated in the signaling cascades controlling axial eye growth.
According to the pathway-analysis software, they represent links between several proteins whose mRNA expression was
changed in our study.
Myopia is becoming an increasing problem, especially in
industrial nations. It is widely believed that both hereditary
and environmental factors contribute to the development of
myopia. Several molecules have already been identified in the
retina that appear to be involved in the visual control of axial
elongation  of  the  eye  (e.g.,  dopamine  [1-3],  retinoic  acid
[4-6],  nitric  oxide  [7-9],  vasoactive  intestinal  polypeptide
[10-12]). Another factor that was found to be involved was
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the  transcription  factor  Egr-1  (early  growth  response
protein-1),  the  mammalian  ortholog  to  the  avian  protein
ZENK (also called Tis8, Ngfi-A, Kro×−24, Zif268 in other
species). By means of immunocytochemistry it was initially
found that the number of ZENK-immunoreactive amacrine
cells in the retina of chicks is increased under conditions that
lead to a reduction in eye growth (myopic defocus, recovery
of  myopia)  and  decreased  under  conditions  that  enhance
ocular growth (hyperopic defocus, form-deprivation). These
changes were most prominent and distinct in a specific subset
of  amacrine  cells,  the  glucagon-containing  amacrine  cells
[13,14]. Recently, this bi-directional response was detected
by  means  of  immunohistochemistry  in  another  glucagon-
containing cell type of the chicken retina as well, the so-called
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2720bullwhip-cells [15]. Moreover, a downregulation of Egr-1
mRNA in total retinal tissue was found in mice after short
periods of form-deprivation [16]. All of these experiments
suggested  that  Egr-1  (ZENK)  is  an  important  factor  in
controlling eye growth, at least in some animal models for
myopia. However, it should be noticed that mRNA levels of
Egr-1 in the total retina of chicks do not seem to show this
bidirectional response consistently. Although ZENK mRNA
levels are upregulated in total retinal samples within one hour
after  diffuser  removal  of  former  form-deprived  chicks
(recovery of myopia) [17], treatment with both minus lenses
and plus lenses for one day reduced the amount of ZENK
mRNA in the total retina of chicks in both cases, suggesting
that the role of Egr-1 is complex and may vary among special
cell types [18,19]. Unfortunately, no study is available that
investigated  the  time  course  of  Egr-1  mRNA  changes  in
detail. Therefore, current knowledge about the regulation of
Egr-1  during  increased  or  decreased  eye  growth  is  still
limited.
Studies on Egr-1 knockout mice were in line with the
hypothesis that Egr-1 has a function in the regulation of eye
growth.  Homozygous  knockout  mice,  lacking  functional
Egr-1 protein, developed relative axial myopia at the age of
42 and 56 days (compared to heterozygous and wild-type
Egr-1 knockout mice [20]). The difference in axial length
declined  with  increasing  age,  but  the  differences  in  the
refractive state persisted. Paraxial schematic eye modeling
suggested that other optical elements, possibly the lens, had
also  changed  in  the  Egr-1  knockout  mice.  This  is  not
surprising, given that Egr-1 was absent not only from retinal
amacrine cells but from all cells of the body. The effect of
lacking Egr-1 protein should have long-ranging effects on
other  cells  in  the  retina,  eye,  and  the  autonomic  nervous
system or the endocrine system.
Egr-1 is known to have a function in a variety of biologic
processes (e.g., cell proliferation [21], brain plasticity and
learning [22], apoptosis [23]) and several target genes of Egr-1
have  already  been  identified.  Egr-1-overexpression  in
synovial  fibroblasts  leads  to  an  increased  expression  of
collagen type 1 and of tissue inhibitor of metalloproteinases
type 1 and 3 (TIMP1 and TIMP3) [24]. Since the induction of
myopia is associated with scleral thinning through reduced
accumulation of collagen and increased degradation of scleral
tissue  [25-27],  the  reduction  of  Egr-1-stimulated  collagen
expression and the reduced inhibition of degrading enzymes
(such as the matrix-metalloproteinases that are repressed by
TIMPs) that could take place in animals without functional
Egr-1 protein, could explain the myopic phenotype of these
mice. Other genes that are already known to be influenced by
Egr-1 are for instance platelet-derived growth factor-A and -
B (PDGF-A and -B) [28,29], basic fibroblast growth factor
(bFGF) [30] and transforming growth factor-beta (TGF-β)
[31].
Because of the complex role of Egr-1 in the regulation of
various other proteins, and the differences in axial eye length
between the Egr-1 knockout mice and the wild-type mice, we
have studied the role of Egr-1 in the retina in more detail.
Retinal samples of Egr-1 knockout and wild-type mice at the
age of 30 days (no difference in axial eye length yet) and 42
days (already a difference in axial eye length of 59 µm) were
compared regarding their mRNA expression changes, both
between the two genotypes and within the same genotype
between the two age groups.
METHODS
Animals: Experiments were conducted in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision  Research  and  were  approved  by  the  University
Commission  for  Animal  Welfare.  Egr-1  knockout  mice,
generated  on  C57/BL6  background,  were  purchased  from
Taconic (Ry, Denmark) and bred in the animal facilities of the
institute after a breeding permission was obtained from the
company.  Since  female  homozygous  knockout  mice  are
sterile because of a deficiency of luteinizing hormone-beta
(which is due to the lack of Egr-1 [32]), only heterozygous
females were bred. Animals were housed in standard cages
with  their  littermates  under  a  12  h  light/dark  cycle  with
unrestricted access to water and food pellets. Illumination was
provided  by  standard  fluorescent  lamps  and  was
approximately  200  lx.  Standard  PCR  was  performed  to
determine genotype (specific primer sequences provided by
Taconic) and gender (with primers designed for the gene
encoding the sex-determining region Y represents as SRY).
Male mice were killed by an overdose of diethyl ether at
the mean age of 30 days (p29-p31) or 42 days (p41-p43). Eyes
were enucleated and retinas were prepared carefully to ensure
that the samples were not contaminated with retinal pigment
epithelium. Tissue was snap-frozen in liquid nitrogen. The
retinas of 12 homozygous Egr-1 knockout mice (hm) and 12
wild-type mice (wt) of the same strain were prepared for both
time points (48 animals in total). Three single retinas from
different mice were then pooled to obtain four samples per
group (wt/30, wt/42, hm/30, hm/42), and RNA was isolated
using  the  RNeasy  Mini  Kit  (Qiagen,  Hilden,  Germany)
according to the manufacturer's instructions.
Microarray: Quality check of RNA, cDNA synthesis and
labeling and the actual microarray analysis was performed by
the  Affymetrix  Resource  Facility  at  the  University  of
Tuebingen.  The  quality  of  total  RNA  was  monitored  by
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA) following the manufacturer's instructions. Generation of
double-stranded cDNA, preparation and labeling of cRNA,
hybridization to 430 2.0 Mouse Genome Arrays (Affymetrix,
Santa Clara, CA), washing, and scanning were performed
according to the standard Affymetrix protocol. Scanning and
analysis were performed using the Affymetrix Microarray
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2721Suite Software (version 5.0) and the signal intensities were
analyzed using ArrayAssist 5.5.1 (Stratagene, La Jolla, CA).
Data were normalized using the GC-RMA normalization
method  which  uses  the  GC  content  of  the  probes  in
normalization with RMA (Robust Multi-Array). To correct
for multiple testing, a false-discovery rate of 5% was applied.
All comparisons of mRNA expression levels between the
groups were performed using un-paired t-tests. Genes were
identified as differentially expressed if they showed a fold-
change (FC) of at least 1.5 with a p value lower than 0.05. Fold
change was calculated by dividing the experimental value
(lens-treated, t) by the control value (untreated control, c). If
the relative signal intensity of the control was higher than the
intensity of the treated samples, the negative reciprocal was
calculated (-c/t). A fold change of 1 or −1 therefore indicates
no change, while a fold change of 2 equals a doubling in
product, and a fold change of −2 equals a halving in transcript
abundance.
The  data  discussed  in  this  publication  have  been
deposited  in  the  National  Center  for  Biotechnology
Information (NCBI's) Gene Expression Omnibus (GEO) and
are  accessible  through  GEO  Series  accession  number
GSE16974.
Pathway analysis: The list of differently expressed genes was
subjected to a subsequent post-analysis task to find the main
biologic processes associated with the experimental system.
The  “Ingenuity  Pathways  Analysis”  Software  5.0  (IPA,
Ingenuity  Systems)  was  applied  to  elucidate  putative
pathways associated with the gene expression changes in the
retinas of the Egr-1 knockout mice between the age of 30 days
and 42 days. For this purpose, 215 genes which were classed
as “differently expressed,” e.g., those whose retinal mRNA
expression in the knockout mice at p30 was significantly
different  from  the  expression  at  p42,  were  analyzed  and
theoretical networks and pathways were computed. The IPA
is a manually curated database of functional interactions and
contains previously published findings from peer-reviewed
publications. Interactions between proteins and molecules in
the proposed networks are therefore supported by published
information which is associated by the program with known
biologic pathways. It should be noted here that the interactions
presented in the networks are not specific for the retina or
brain tissue, as the database contains literature from many
different research areas. If the mRNA expression levels of
many proteins present in one proposed network have actually
been found to be changed, it is likely that they are connected
with  each  other  and  that  their  changes  may  represent  a
response to the lack of Egr-1.
Real-time RT–PCR: Based on three networks found in the
homozygous Egr-1 knockout mice computed by Ingenuity
Pathways Analysis Software (hm/30 versus hm/42, see Figure
1A-C), nine genes were chosen for further validation of their
expression changes by real-time RT–PCR (three genes per
network). For network A we chose: A kinase anchor protein
9  (Akap9),  SET  domain,  bifurcated  1  (Setdb1)  and
staphylococcal  nuclease  domain  containing  1  (Snd1).  The
three  genes  representing  network  B  were:  corticotropin
releasing hormone (Crh), insulin-like growth factor binding
protein  3  (Igfbp3),  and  LIM  and  SH3  protein  1  (Lasp1).
Finally,  from  network  C  we  chose:  nuclear  prelamin  A
recognition  factor  (Narf),  oxoglutarate  dehydrogenase
(Ogdh),  and  selenium  binding  protein  1  (Selenbp1).  In
addition, protocadherin-beta 9 (Pcdhb9), the gene that showed
the  highest  fold-change  in  mRNA  expression  levels  in  a
comparison between wild-type and knockout mice, was tested
with real-time PCR.
The primer sequences, product lengths, NCBI accession
numbers and network classifications of the genes tested are
shown in Table 1. From each sample, 1 µg of RNA was reverse
transcribed using M-MLV reverse transcriptase (Promega,
Mannheim, Germany), 500 ng oligo (dT)15 primer and 50 ng
of a random primer mixture (Invitrogen, Solingen, Germany).
Semiquantitative real-time RT–PCR was performed with the
aid of QuantiTect SYBR Green master mix kit of Qiagen on
the iCycler iQ Multicolor Real-Time PCR Detection System
from Bio-Rad (Hercules, CA). All samples were analyzed in
triplicate with a template amount corresponding to 2 ng of
RNA.  Hypoxanthine-phosphoribosyl-transferase  (HPRT)
was used as a housekeeping gene and all PCR products were
subjected to automated sequencing to ensure amplification of
the correct sequences.
Statistics and data analysis: Data were analyzed using the
software  JMP  5.1  (SAS  Institute,  Cary,  NC)  and  Excel
(Microsoft  Corporation,  Redmond,  WA).  The  mean  cycle
threshold (Ct) value of each triplet was taken and the mean
normalized expression (MNE) was computed as previously
described [33]. To test for differences between the four groups
(wt/30, wt/42, hm/30, hm/42), ANOVA’s (ANOVA) were
applied for each gene. In case the ANOVA was significant
(p<0.05), a paired Student's t-test was applied as a post-hoc
test to test for differences between wt/30 versus wt/42 and hm/
30 versus hm/42.
RESULTS
Microarray:
Age-related comparisons (wt/30 versus wt/42) in wild-
type mice—Comparing mRNA expression levels between the
30 days old and the 42 days old wild-type mice, 54 genes were
classified as differentially expressed (with a minimum FC of
±1.5 and a p-value lower than 0.05). The corresponding genes
are listed in Appendix 1 together with the fold-changes and p-
values that were determined in homozygous Egr-1 knockout
mice at the two ages. Seventeen genes showed reduced mRNA
expression in the 42 days old wild-type mice compared to the
30 days old mice. Thirty-seven genes were higher expressed.
The  maximum  fold-changes  were  −2.40  and  2.62,
respectively.
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2722Figure 1. Networks predicted by Ingenuity Pathway Analysis in the homozygous Egr-1 knockout mice. Networks proposed by Ingenuity
Pathways Analysis Software. All genes whose mRNA expression levels were found to be differentially regulated in the knockout mice between
the age of 30 days and 42 days are highlighted in gray. Encircled are those genes that were chosen for validation by real-time RT–PCR. A
detailed legend describing the symbols used in this scheme is enclosed in the figure. Asterisks denote changes in gene expression that were
validated using real-time PCR.
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knockout mice: Two hundred fifteen genes had changed their
expression levels in the homozygous Egr-1 knockout mice
between the age of 30 and 42 days (see Appendix 2 for a list
of those genes). Higher mRNA expression was found in 176
genes at 42 days, compared to 30 days, while 39 genes showed
reduced mRNA expression. Age-dependent changes in gene
expression ranged here between 2.49 fold and −4.01 fold. A
pathway  analysis  was  performed  based  on  this  list  of
differentially expressed genes. Genes that were further studied
using semiquantitative real-time RT–PCR are shown in bold
in Appendix 2.
Eight genes were differently expressed at the two ages in
both wild-type and homozygous Egr-1 knockout mice (shown
in italics and underlined in Appendix 1 and Appendix 2). The
directions of their changes were the same in wild-type- and
homozygous Egr-1 knockout mice.
Egr-1-related comparisons (wt/30 versus hm/30 and wt/42
versus hm/42): In the 30 days old mice, the lack of Egr-1 was
associated  with  different  mRNA  expression  levels  of  73
genes,  with  39  upregulated  and  34  downregulated  (wt/30
versus hm/30, see Table 2 for a list of those genes). In the 42
days  old  mice,  135  genes  were  differently  expressed
compared to the wild-type. One hundred and thirteen genes
were upregulated, and 22 genes were downregulated (wt/42
versus hm/42, see Table 3 for a list of those genes).
Thirteen genes showed up in both lists (shown in italics
and underlined in both Table 2 and Table 3) and except for
one  gene  (dystrophin  (DMD)),  the  regulation  of  mRNA
expression levels was in the same direction at both 30 days
and 42 days. The gene that showed the highest difference in
mRNA expression levels (Pcdhb9, shown in bold in Table 2
and Table 3), was further studied using semiquantitative real-
time RT–PCR.
Pathway  analyses:  Data  obtained  by  comparison  of  the
mRNA  expression  patterns  in  the  homozygous  Egr-1
knockout mice between the age of 30 days and 42 days (hm/
30 versus hm/42, see Appendix 2, 215 genes) were analyzed
using the software “Ingenuity Pathway Analysis.” Several
networks were identified that could be involved in retinal
signaling. We chose three networks that appeared different in
the homozygous Egr-1 knockout mice (see Figure 1A-C) to
find  candidates  for  validation  by  real-time  RT–PCR.
Networks proposed by the software were common signaling
pathways.  All  genes  that  were  found  to  be  differently
expressed in the knockout mice are indicated by filled gray
symbols in Figure 1. Genes labeled as open symbols represent
intermediate metabolic steps, determined from the current
literature by the software. Molecules represented in network
A (Figure 1A) are regulated by mitogen-activated protein
kinases (MAPK), which respond to a variety of extracellular
stimuli and regulate various cellular activities, such as gene
expression,  mitosis,  differentiation,  and  cell  survival/
apoptosis [34]. These kinases seem to be effector proteins in
network B (Figure 1B) as well, together with insulin, the early
response transcription factor activator-protein 1 (Ap1) and
another ubiquitous transcription factor, nuclear factor-kappa
B (NfkB). The central molecules in network C (Figure 1C) are
retinoic acid, vascular endothelial growth factor A (Vegf-A),
V-fos  FBJ  murine  osteosarcoma  viral  oncogene  homolog
(Fos) and beta-estradiol.
Furthermore, several pathways were identified in both the
wild-type and the homozygous knockout mice (wt/30 versus
wt/42 and hm/30 versus hm/42, shown in Table 4). The lack
of Egr-1 seems to affect a variety of pathways and many
fundamental pathways are part of this list (e.g., synaptic long-
term  depression  and  potentiation,  PDGF-  and  chemokine
signaling, and others).
Real-time RT–PCR: Based on the three networks identified
by Ingenuity Pathways Analysis Software (hm/30 versus hm/
42, Figure 1A-C), nine genes were chosen for validation of
their changes in mRNA expression by real-time RT–PCR,
with  three  genes  present  in  each  network.  In  addition,
protocadherin-beta  9  (Pcdhb9),  the  gene  that  showed  the
highest fold-change in comparison between the wild-type and
TABLE 1. DESCRIPTION OF PRIMERS.
Gene
NCBI accession
number Forward primer (5′-3′) Reverse primer (5′-3′) Amplicon Network
Akap9 NM_194462.2 GTCTTCAGATGGTAGAAAAGGA GTTAGCTGTGAGCTGAGTTATG 173 bp A
Setdb1 NM_018877.2 GATAGCTCCTGCCGAGACTTC CTGCCATCCACCTCTTCAAC 143 bp A
Snd1 NM_019776.2 ACGCTGATGAGTTTGGCTACA CCACGACAGAGGAGGTTTC 171 bp A
Crh NM_205769.1 CATTCTTGAGGGGTGGCTA CTCTTACACAACCAAATTGACC 116 bp B
Igfbp3 NM_008343.2 TCTTGGGGTCCTTCTCAAA CCTCCAGACACAGGCTCC 194 bp B
Lasp1 NM_010688.3 ATACCATGAGGAGTTTGAGAAG ACCATAGGACGAGGTCATCT 196 bp B
Narf NM_026272.2 GATAGCATCCCTTCAGCCCT TTCATCAAACCCCTTTATCTCC 156 bp C
Ogdh NM_010956.3 GCTAGTCTCTTCCTTGACTG AACTTACTCATGCCATTGTC 184 bp C
Selenbp1 NM_009150.3 GTGCAACGTGAGCAGTTT CTGCATCCCCAGGCTTCT 161 bp C
Pcdhb9 NM_053134.3 TTTAGGAGAAACTACCTTGTGC TGAGCATTAAAGTCACTTGAGG 195 bp none
HRPT NM_013556.2 CCAGTAAAATTAGCAGGTGTTC GATAAGCGACAATCTACCAGAG 179 bp none
Shown are the NCBI accession numbers, primer sequences, product sizes and the assignment to the networks of the genes that
were further tested with real-time RT–PCR.
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2731the  knockout  mice  (wt/30  versus  hm/30:  14-fold  lower
expressed in the homozygous mice and wt/42 versus hm/42:
17-fold lower expressed) was tested with real-time RT–PCR.
The changes in mRNA expression levels of four of the genes
could be validated (Figure 2). Three of them were chosen
based on network C (Narf, Ogdh, and Selenbp1) and the gene
which showed the biggest difference in mRNA expression
levels between wild-type and knockout mice, Pcdhb9, was
also confirmed.
The relative signal intensities obtained by microarray
analysis (GC-RMA based, shown are the log transformed
mean relative signal intensities ±SD, n=4 each) of all four
groups tested are shown in Figure 2, upper graphs. The lower
graphs shows the mean MNE-values ±SD obtained by real-
time RT–PCR (n=4 each). The results of the ANOVA is
indicated in the header of the figures for each gene and the
fold-changes (FC) and p values (p) of the un-paired Student's
t-tests as post-hoc tests for the comparisons between the 30
days old mice and the 42 days old mice are shown within the
graphs.
Note that the comparison of the Pcdhb9 expression is not
between  the  two  age  groups,  but  between  homozygous
knockout mice and wild-type mice at both time points.
Nuclear prelamin A recognition factor (Narf) was lower
expressed in the 42 days old homozygous mice, compared to
the 30 days old mice in both the microarray analysis (hm/42
versus hm/30: −1.65 fold, p<0.001) and the real-time PCR
experiment (−1.53 fold, p<0.05). The mRNA expression did
not differ in the wild-type mice over time in either experiment.
Also Oxoglutarate dehydrogenase (Ogdh) was different
only in the homozygous Egr-1 knockout mice and showed no
changes in mRNA expression levels over time in the wild-
type.  Post-hoc  analysis  confirmed  that  mRNA  expression
levels in the 30 day-old homozygous mice was significantly
lower, compared to 42 day-old animals (hm/30 versus hm/42:
1.69-fold, with p<0.01 in the MA experiment and 1.51 fold
with p<0.01 in the PCR experiment).
The mRNA expression levels of selenium binding protein
1 (Selenbp1) were higher in the 30 days old knockout mice,
compared to the 42 days old homozygous mice (hm/42 versus
hm/30: −2.52 fold with p<0.001 in the MA experiment and
TABLE 4. PATHWAYS IDENTIFIED IN THE WILD-TYPE AND THE HOMOZYGOUS EGR-1 KNOCKOUT MICE BY INGENUITY PATHWAY ANALYSIS SOFTWARE
(WT/30 VERSUS WT/42 AND HM/30 VERSUS HM/42).
Pathways detected in wild-type mice (30 days versus 42 days, 54 differentially expressed genes):
Pathway Molecules
Arachidonic Acid Metabolism Gpx3, Cyp2d6, Ptgds
Acute Phase Response Signaling Ttr, Tf, A2m
FXR/RXR Activation Pon1, Cyp27a1
Pathways detected in Egr-1 knockout-mice (30 days versus 42 days, 215 differentially expressed genes):
Pathway Molecules
Synaptic Long-term Depression Plcb4, Itpr2, Igf1r, Gna13, Prkca, Prkcb1
Synaptic Long-term Potentiation Plcb4, Itpr2, Atf2, Prkca, Prkcb1
Huntington's Disease Signaling Gnb1, Plcb4, Igf1r, Zdhhc17, Atf2, Prkca, Prkcb1
PDGF Signaling Crkl, Abl1, Prkca, Prkcb1
Chemokine Signaling Plcb4, Ppp1r12b, Prkca, Prkcb1
VDR/RXR Activation Igfbp3, Ncoa1, Prkca, Prkcb1
FGF Signaling Crkl, Fgf11, Atf2, Prkca
Ephrin Receptor Signaling Gnb1, Crkl, Abl1, Gna13, Atf2, Rapgef1
Axonal Guidance Signaling Gnb1, Plcb4, Pfn1, Crkl, Abl1, Gna13, Prkca, Prkcb1
Lysine Degradation Setdb1, Nsd1, Ogdh
Actin Cytoskeleton Signaling Pfn1, Diaph3, Crkl, Ppp1r12b, Fgf11, Gna13
Circadian Rhythm Signaling Arntl, Atf2
G-Protein Coupled Receptor Signaling Pde8a, Plcb4, Atf2, Prkca, Prkcb1
Integrin Signaling Tspan5, Crkl, Ppp1r12b, Abl1, Rapgef1
Neuregulin Signaling Crkl, Prkca, Prkcb1
SAPK/JNK Signaling Gnb1, Crkl, Gna13, Atf2
ERK/MAPK Signaling Crkl, Atf2, Rapgef1, Prkca, Prkcb1
Shown are the descriptions of the pathways and the molecules involved in both the wild-type and the homozygous Egr-1   knockout
mice that changed their mRNA expression patterns over the investigated period of time (p30 versus p42) based on Ingenuity
Pathway Analysis Software.
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2732−2.23 fold with p<0.001 in the PCR experiment) and again,
no such changes were observed in the wild-type.
In  case  of  protocadherin-beta  9  (Pcdhb9),  mRNA
expression levels did not change with age, but were much
lower  in  the  knockout  mice.  Real-time  PCR  detected  a
fivefold decline in the expression of Pcdhb9 in knockout mice,
both  at  p30  and  at  p42,  whereas  the  microarray  analysis
determined an even larger decline (hm/30 versus wt/30: −14
fold and hm/42 versus wt/42: −17 fold, with p<0.001 each).
DISCUSSION
Earlier studies suggested that Egr-1 might play a role in eye
growth regulation in chicks [13] and mice [20,35]. The current
study attempted to determine which genes were differentially
regulated  in  Egr-1  knockout  mice  at  two  different
developmental stages. Since Egr-1 knockout mice had longer
eyes at age 42 days, compared to wild-type mice, but not at
day 30, it was hoped that a correlation could be found between
the expression of certain genes and changes in eye growth.
Furthermore, it was hoped that some of the changes might
occur that relate to genes or factors that are already known to
be involved in the regulation of axial eye growth in animal
models.
The analysis of retinal gene expression in homozygous
Egr-1 knockout mice and wild-type mice at different ages
(p30 and p42) provided a huge amount of data. Depending on
the  comparisons  (wild-type  versus  homozygous,  30  days
versus 42 days), different information about gene expression
were obtained and different conclusions could be drawn. The
focus in this paper was on changes that occur in homozygous
Egr-1 knockout mice and wild-type mice between 30 and 42
days (wt/30 versus wt/42 and hm/30 versus hm/42). Some
consistent changes in mRNA expression patterns were found
in the Egr-1 knockout mice compared to wild-type mice.
Whether these genes are directly involved in the temporarily
Figure  2.  Genes  whose  mRNA
expression levels could be validated by
real-time  RT–PCR.  Mean  relative
expression values ±SD (n=4) obtained
by  microarray  analysis  and  mean
normalized expression values obtained
by real-time PCR (n=4). The p-values of
the ANOVA's can be seen in the heading
of the figures. The fold-changes and p-
values  (determined  by  un-paired
Student's  t-test  as  post-hoc  analysis)
were  computed  for  the  comparison
between  30  days  and  42  days  old
knockout-  and  wild-type  mice  (wt/30
versus wt/42 and hm/30 versus. hm/42)
and are shown within the figures. Please
note  that  in  the  case  of  Pcdhb9,  the
comparison  is  between  the  knockout
and the wild-type mice at both ages (wt/
30 versus. hm/30 and wt42 versus hm/
42).
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2733enhanced axial eye growth, or represent just epiphenomena,
remains undefined and needs to be determined by further
studies.
Microarray:
Gene expression changes over time (p30 versus p42)
—It was not surprising that in wild-type mice only 54 genes
showed  differential  mRNA  expression  over  time  (wt/30
versus  wt/42,  see  Appendix  1),  since  the  mouse  retina  is
generally considered to be mature at the age of about p21
[36]. In the homozygous Egr-1 knockout mice, 215 genes
(roughly four times as many) were differently expressed (hm/
30 versus hm/42, Appendix 2). Eight genes showed similar
changes in mRNA expression in both the homozygous and the
wild-type  Egr-1  knockout  mice  (shown  in  italics  and
underlined  in  Appendix  1  and  Appendix  2).  They  likely
encode for proteins that are involved in normal retinal function
and  are  not  related  to  the  abnormal  ocular  growth  in  the
knockout mice.
The  average  mean  fold-changes  in  this  study  were
1.48±0.41,  which  is  in  line  with  findings  from  other
microarray studies [16,19,37,38]. It has to be kept in mind that
global  gene  expression  measurements  in  a  heterogeneous
tissue  like  the  retina  are  difficult  to  interpret  since  large
changes in mRNA expression in a subset of cells might be
obscured by changes in the opposite direction in a different,
perhaps even more abundant population of cells. For the same
reason, large changes in mRNA expression in a rare cell type
might  go  unnoticed  because  they  generate  only  a  small
fraction  of  the  total  mRNA.  In  the  future,  quantitative
immunohistochemistry might help to detect changes in gene
products which are localized to certain cells types.
Differences in gene expression in Egr-1 knockout mice
and  their  wild-type:  Thirteen  genes  were  differentially
expressed in knockout mice, compared to wild-type, at both
ages tested (Table 2 and Table 3: genes are shown in italics
and underlined). Except for dystrophin (DMD), the regulation
of those genes was in the same direction at both ages. These
genes are therefore most probably target genes of Egr-1 and
are not directly related to the developmental changes observed
in these mice. Nevertheless, these thirteen genes are of interest
because they were not previously described as possible targets
for the Egr-1 protein. Still, whether the interaction with the
Egr-1 protein is direct or indirect, has yet to be experimentally
validated  using  other  techniques  like  chromatin
immunoprecipitation. The Egr-1 knockout mice used in our
study contain several in-frame stop codons in the Egr-1 coding
sequence, upstream of the zinc finger DNA binding domain.
Parts of the mRNA sequence of Egr-1 can therefore still be
transcribed  but  the  stop-codons  lead  to  the  functional
elimination of the protein Egr1. The truncated Egr-1 mRNAs
can still bind to the microarray. Upregulation of Egr-1 mRNA
itself in the knockout mice can be explained by the fact that
Egr-1 can suppress its own expression, as has been shown in
tissue  culture  [39].  A  negative  feedback  mechanism  has
already been described elsewhere and can be seen for Nab2
(Ngfi-A-binding protein-2) [40]. This protein was massively
downregulated in Egr-1 knockout mice and is assumed to be
a major regulator of Egr-1 function, since it is induced by the
same stimuli that induce Egr-1. Dystrophin (DMD) mRNA
expression  was  lower  at  p30  in  the  homozygous  mice,
compared  to  the  wild-type  mice,  and  higher  at  p42.  An
enhanced  DMD  content  may  therefore  be  correlated  with
enhanced axial eye growth. DMD is a plasma membrane-
associated cytoskeletal protein of the spectrin superfamily and
its absence or functional deficiency is the cause of several
types of muscular dystrophies in humans. In some of these
patients, retinal function is affected as well, as reflected in a
reduced  b-wave  in  the  electroretinograms  (ERG).  DMD
isoforms  have  been  localized  to  Müller  cells  and
photoreceptor terminals, so the abnormality in the ERGs is
most likely due to a disturbance of neurotransmission between
photoreceptors and ON-bipolar cells [41]. Interestingly, the
lack  of  the  dystrophin  isoform  Dp71  leads  to  impaired
clustering of two Müller glia cell proteins in mice, namely the
inwardly rectifying potassium channel Kir4.1 and the water
pore aquaporin 4 (AQP4) [42]. Both Kir4.1 and AQP4 have
already been implicated in the development of myopia and
their role as a conduit for movement of retinal fluid into the
vitreous was suggested [43,44].
Protocadherin  beta  9  (Pcdhb9)  was  the  most  heavily
regulated gene in this study (wt/30 versus hm/30: 14-fold
downregulated  and  wt/42  versus  hm/42:  17-fold
downregulated in the homozygous Egr-1 knockout mice).
Protocadherins  are  calcium-dependent  cell–cell  adhesion
molecules. Their specific functions are unknown, but they
most  likely  play  a  critical  role  in  the  establishment  and
function of specific cell-cell neural connections [45]. The
massive downregulation of this gene suggests a tight control,
either directly by Egr-1, or indirectly by other Egr-1-regulated
genes.
Ingenuity pathway analysis: The list of genes that were
differentially expressed in the Egr-1 knockout mice between
the age of 30 and 42 days (hm/30 versus hm/42) was analyzed
using Ingenuity Pathway Analysis Software. Many ubiquitous
signaling  pathways  in  the  retina  seem  to  be  involved.
Therefore,  it  is  difficult  to  define  those  genes  that  are
responsible for the development of the relative myopia in the
42-day-old Egr-1 knockout mice. As can be seen in Figures
1A-C, genes that showed altered mRNA expression in this
study were not the key regulators in the functional networks
proposed by the software. As already mentioned above, these
pathway schemes are based on known interactions between
molecules.  They  provide  only  suggestions  for  possible
interactions. Involvement of the intermediate proteins and co-
factors  in  these  pathways  is,  therefore,  possible  but  not
proven. Furthermore, since the changes in mRNA expression
levels of any gene chosen from network A and B could not be
Molecular Vision 2009; 15:2720-2739 <http://www.molvis.org/molvis/v15/a288> © 2009 Molecular Vision
2734validated in all cases, it is difficult to speculate about the
involvement of these networks as illustrated in Figure 1.
The  only  data  available  on  visual  function  in  Egr-1
knockout mice are from optomotor experiments. They did not
show  any  differences  in  contrast  sensitivity  or  spatial
resolution to the wild-type [20]. Interestingly, the lack of
Egr-1 does not seem to affect other sensory systems in the
mouse,  like  the  auditory  system.  Auditory  function  was
studied  by  evoked  brainstem  responses  (ABR)  and
otoacoustic  emissions  (DPOAE),  but  no  differences  were
found  between  wild-types  and  knockout  mice  (Dr.  Lukas
Rüttiger,  Tuebingen  Hearing  Research  Centre  [THRC],
Tuebingen,  Germany,  personal  communication  2008).
Therefore the function of Egr-1 in the regulation of axial eye
growth seems to be quite specific despite the fact that common
signaling pathways were affected.
Real-time RT–PCR:
Validation of genes—The mRNA expression levels of
four out of the ten tested genes could be validated (Figure 2).
To  be  able  to  compare  the  relative  expression  levels  as
determined by microarray analysis (MA) and real-time PCR
(PCR) easily, Figure 2 shows the results of MA and PCR
experiments separately for each gene. Non-validated genes
are  not  represented  in  this  figure.  The  fold-changes
determined by PCR and MA of Narf, Ogdh, and Selenbp1
were  very  similar  whereas  for  Pcdhb9,  the  magnitude  of
changes was severely overestimated by MA. Considering this
fact,  the  involvement  of  network  A  and  B  is  more
questionable, since none of the genes tested with real-time
PCR could be validated. On the other hand, only three genes
were tested in each network, and others which would have
been validated upon testing might have been overlooked. Our
primers were designed to bind to the same part of the sequence
that  was  detected  by  the  oligonucleotide  probes  on  the
Affymetrix chip (to avoid detection of different isoforms) and
should  have  been  appropriate  to  validate  the  microarray
results. The applied false-discovery-rate of 5% thus does not
seem to reflect the true errors that are unavoidable in this
technique. These observations confirm that validation of the
results of microarray analyses by other techniques (in this case
semiquantitative real-time RT–PCR) should be mandatory.
Genes  whose  transcription  could  be  validated:  The
functions of the three genes which could be validated with
real-time PCR are described in more detail below:
Narf—The  expression  of  Nuclear  prelamin  A
recognition factor was found to be lowest in the 42 days old
knockout mice. Prenylation and methylation occurs at the C-
terminal  end  of  proteins  and  was  initially  believed  to  be
important only for membrane attachment. However, another
role for prenylation appears to be the mediation of protein–
protein interactions [46]. The only nuclear proteins known to
be prenylated in mammalian cells are prelamin A- and B-type
lamins.  Lamins  are  fibrous  proteins  providing  structural
function and transcriptional regulation in the cell nucleus, but
the cellular role of both the prenylated prelamin A precursor
and Narf, which is known to bind to the farnesylated prelamin
A, is unknown and its role in the retina is unclear.
Ogdh—Oxoglutarate dehydrogenase mRNA expression
was  significantly  enhanced  in  42-day-old  knockout  mice.
Ogdh is a mitochondrial enzyme complex, comprising of three
different  subunits  (Ogdh,  Dld,  Dlst)  that  converts  2-
oxoglutatate into succinyl-CoA and carbon dioxide in the
Krebs cycle. Its reduction in patients with Alzheimer disease
suggests an altered metabolism of the nervous tissue [47].
Unfortunately, no information is available yet for the role of
this enzyme in the retina, but it could well be that the changes
in mRNA expression of this gene reflects changes in the
metabolic  rate  of  retinal  cells  in  the  homozygous  Egr-1
knockout mice.
Selenbp1—Egr-1  knockout  mice  showed  a  high
expression  of  Selenbp1  at  the  age  of  30  days,  with  a
subsequent decline. Selenium binding protein has been shown
in several studies to be downregulated in cancer [48,49]. A
protective  effect  of  selenium  in  preventing  macular
degeneration has also been shown [50] and another selenium
transporter (selenoprotein P) has been found to be upregulated
in the retina of chicks that were treated with either positive or
negative lenses [51]. Selenbp1 expression can be blocked by
TGF-β in smooth muscle cells [52] and this protein (TGF-β)
has already been implicated in myopia [53,54] and in the
regulation of programmed cell death in the retina [55]. The
role of selenium and its associated binding proteins in the
retina of Egr-1 knockout mice merits further investigation.
Involvement of network C: Although the genes for which
expression changes could be validated belong to this network,
the involvement of the “key molecules” presented in Figure
1C remains speculative. No mRNA expression changes of
e.g., VEGF, cFos, or EGF were found in this study although
oligonucleotides  representing  mRNAs  of  VEGF,  cFos,
EGF, and retinoic acid receptors are present on the Affymetrix
chip used in this study. Obviously, the lack of functional Egr-1
protein did not affect mRNA expression levels of these genes.
Nevertheless, some of those molecules have already been
proposed to play a role in the regulation of eye growth, or were
shown to change in the retina in response to various optical
stimuli [4-6,13,16,56-62]. The fact that they seem to link
several  factors  that  were  found  to  have  changed  mRNA
expression levels in Egr-1 knockout mice is in line with the
idea that these molecules are involved in the regulation of eye
growth.
Outlook: This study provided a list of genes that appear
associated with Egr-1 signaling and/or altered eye growth in
Egr-1 knockout mice. It is difficult to define specific roles to
those  genes  in  eye  growth  in  the  Egr-1  knockout  mice.
Analysis of possibly involved networks show that the lack of
Egr-1 affects common pathways in the retina. Furthermore,
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role as well, perhaps partially taking over the role of Egr-1 in
the  retina  of  Egr-1  knockout  mice.  We  believe  that  the
microarray  analysis  is  a  powerful  tool  to  detect  NEW
candidates, rather than to look at the “usual suspects.” It is,
however,  difficult  to  use  the  microarray  technology  in
heterogeneous  tissue  like  retina.  There  are  now  advanced
methods available to focus on certain cell types (e.g., laser
capture microdissection of fluorescent-activated cell sorting).
Nevertheless, some interesting genes were found in this study.
In addition, several direct or indirect target genes of Egr-1
could be identified, including the most prominently regulated
gene protocadherin-beta 9. The list of differentially expressed
genes is accessible online in the Gene Expression Omnibus
(GEO) Database and might be useful not only to researchers
in the field of myopia.
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2738Appendix 1. List of differentially expressed genes in the wild-type mice
between p30 and p42 days (wt/30 versus wt/42).
To access the data, click or select the words “Appendix
1.” This will initiate the download of a (pdf) archive that
contains the file. Affymetrix ID, gene symbol, gene title, fold
change (FC) and p-values of both the wild-type mice and the
homozygous Egr-1 knockout mice are shown. Genes were
sorted after GO annotations. Genes that were significantly
changed (with a FC > 1.5 and p-value < 0.05) in both the wild-
type  mice  and  the  homozygous  Egr-1  knockout  mice  are
shown in italics and are underlined.
Appendix  2.  List  of  genes  that  were  differentially  expressed  in  the
homozygous Egr-1 knockout mice between p30 and p42 (hm/30 versus hm/
42).
To access the data, click or select the words “Appendix
2.” This will initiate the download of an Excel (.xls) file that
contains the file.Affymetrix ID, gene symbol, gene title, fold
change (FC), and p-values of both the homozygous Egr-1
knockout mice and the wild-type mice are shown. Genes were
sorted after GO annotations. Genes that were significantly
changed  (with  a  FC  >1.5  and  p-value  <0.05)  in  both  the
homozygous wild-type mice and the Egr-1 knockout mice are
shown in italics and are underlined. Genes that were chosen
for real-time RT–PCR validation are shown in bold.
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